
Tactile Systems (TCMD) Stock Forecast & Price Target
Tactile Systems (TCMD) Analyst Ratings
Bulls say
Tactile Systems Tech is expected to have a strong financial performance for the year with a projected EBITDA of $49M-$51M and revenue growth of 9%-11%. Despite challenges in their Airway Clearance division, the company remains on track according to their guidance, and has a positive outlook for future growth through opportunities such as the recent Medicare NCD. With a strong presence in the lymphedema market and a focus on improving reimbursement and access to care for patients, TCMD has a Buy rating and a projected 9% CAGR through FY28, though there are potential risks to consider such as slower sales uptake and competition in the airway clearance market.
Bears say
Tactile Systems Tech is facing multiple risks that could hinder its growth in the future, including slower adoption in key commercial channels, competition with Airway Clearance, and uncertainties around the usage of pneumatic compression as a standalone treatment. Additionally, financial metrics such as a projected 6.7% decrease in Airway Clearance revenue and a flat contribution from Lymphedema in FY26 also indicate potential challenges.
This aggregate rating is based on analysts' research of Tactile Systems and is not a guaranteed prediction by Public.com or investment advice.
Tactile Systems (TCMD) Analyst Forecast & Price Prediction
Start investing in Tactile Systems (TCMD)
Order type
Buy in
Order amount
Est. shares
0 shares